Meta-analysis: isotretinoin reduces depression in patients with acne

  • Li C & al.
  • BMJ Open
  • 21 Jan 2019

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review and meta-analysis suggest that use of isotretinoin (Myorisan, Amnesteem, Claravis) is associated with reduced depression symptoms in patients with acne vulgaris, although there is an unclear relationship with risk for depressive disorders.

Why this matters

  • The relationship between isotretinoin and depression risk is controversial.

Key results

  • Overall, isotretinoin was associated with improved depressive symptoms compared with baseline (SMD, −0.33; P<.05 style="list-style-type:circle;">
  • Results were significant for studies using the Hospital Anxiety and Depression Scale-Depression (SMD, −0.57; P<.05 zung self rating depression scale or centre for epidemiologic studies but not those using the beck inventory montogomery-asbery hamilton>
  • Isotretinoin was significantly associated with risk for depressive disorders in 2 retrospective studies (relative risk [RR], 1.39; P=.02), but not in 2 prospective studies (RR, 0.85; P=.86).
  • Study design

    • 20 studies comparing isotretinoin with other interventions in patients with acne were included.
      • 17 studies analyzed use of isotretinoin and depressive symptoms.
      • 4 studies analyzed use of isotretinoin and risk for depression.
    • Funding: None disclosed.

    Limitations

    • Heterogeneity between studies.
    • No randomized, controlled trials were included.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit